ArticleJournal of clinical laboratory analysis2021
Overexpression of sirtuin 2 and its association with prognosis in acute ischemic stroke patients.
Article in Journal of clinical laboratory analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Systematic review and meta-analysis of stroke blood biomarker data highlights need for more translational research methods.Nature communications · 2026Pooled it
- mMolecular neurobiology · 2024Article
- Advances in development of biomarkers for brain damage and ischemia.Molecular biology reports · 2024Review
- Article
- Sirtuins: Promising Therapeutic Targets to Treat Ischemic Stroke.Biomolecules · 2023Review
- SIRT2 plays complex roles in neuroinflammation neuroimmunology-associated disorders.Frontiers in immunology · 2023Review
- The sirtuin family in health and disease.Signal transduction and targeted therapy · 2022Review
- Will Sirtuin 2 Be a Promising Target for Neuroinflammatory Disorders?Frontiers in cellular neuroscience · 2022Review
- Multiple Roles of SIRT2 in Regulating Physiological and Pathological Signal Transduction.Genetics research · 2022Review
- Erratum.Journal of clinical laboratory analysis · 2021Article
Corrections and comments
- Erratum issuedErratum.2021
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the correlation of sirtuin 2 (SIRT2) with acute ischemic stroke (AIS) risk, severity, inflammation, and prognosis.
methodsA hundred and sixty-four first episode AIS patients and 164 age and gender matched non-AIS patients with high-stroke-risk factors (controls) were enrolled. Peripheral blood was collected and serum was separated for SIRT2 and pro-inflammatory cytokines detection by enzyme-linked immunosorbent assay. AIS patients were continually followed up to 36 months or death, then recurrence-free survival (RFS) and overall survival (OS) were calculated.
resultsSerum SIRT2 expression was increased in AIS patients compared to controls (p < 0.001), then receiver operative characteristic curve disclosed that the serum SIRT2 expression could differentiate AIS patients from controls with a good area under curve of 0.890 (95%CI: 0.854-0.926), a sensitivity of 78.7% and a specificity of 91.5% at the best cut-off point. Serum SIRT2 expression was positively correlated with National Institute of Health stroke scale score (p < 0.001), serum tumor necrosis factor-α (p < 0.001), interleukin (IL)-6 (p = 0.012) and IL-17 (p < 0.001) expressions in AIS patients. In addition, serum SIRT2 expression was elevated in recurrent/dead AIS patients compared to non-recurrent/dead AIS patients (p = 0.025), and was also increased in dead AIS patients compared to survivors (p = 0.006). Moreover, RFS (p = 0.029) and OS (p = 0.049) were both worse in AIS patients with SIRT2 high expression compared to AIS patients with SIRT2 low expression.
conclusionSIRT2 may serve as a marker for AIS risk and prognosis in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.